Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Don’t Expand Comparator PMP Removal Rule, Set Deduction Limit for Method II: FPMAJ
June 17, 2019
- Discuss Cost Effectiveness Assessment, Disclosure Ratios Separately: FPMAJ
June 17, 2019
- FPMAJ Calls for Post-Launch Premiums for Add’l Indications, Evidence
June 17, 2019
- Fix Price Maintenance Premium to Make It Fit Its Concept, Revisit Product/Company Criteria: FPMAJ
June 17, 2019
- JPMA Nudges PMDA to Increase Int’l Staffers, Drive Harmonization in Asia
June 12, 2019
- Doctors’ Lobby Voices Opposition to Changing Health Coverage, Copay Rates for Minor Illnesses
June 6, 2019
- Ahead of G20 Summit, Global Pharma Leaders Prod PM Abe to Take Leadership in Addressing Health Challenges
June 5, 2019
- Generic Industry Calls for Support for API Purchase Cost, Revision of Gx Pricing: LDP Study Group
June 3, 2019
- JPMA Asks Govt to Buy 1.3 Billion Yen Cryo-EM Equipment to Fuel Drug Discovery
May 29, 2019
- JPWA Pushing for September Announcement of New NHI Prices
May 27, 2019
- Medipal Pres. Watanabe Elected as New JPWA Chief
May 24, 2019
- Professor Calls for More Balanced Healthcare Resource Allocation, Higher Copay for Minor Illnesses
May 24, 2019
- Hodanren Renews Call for Transparent Pricing for Kymriah
May 23, 2019
- OTC Industry Group to Up Its Efforts to Reduce “Switch Lag”
May 22, 2019
- Sales of Japan CRO Association Members Down 1.2% to 190 Billion Yen in 2018; Pharma Sales Up 2.6%
May 22, 2019
- Wholesaler Group to Set Up Own Rules for Information Provision by Autumn
May 21, 2019
- Kymriah’s 33.5 Million Yen Price Tag Favorably Received by JMA
May 16, 2019
- Payer Reps Stress Need to Revise Coverage of Drugs for Minor Illnesses; Kymriah’s Price Isn’t Necessarily too High
May 16, 2019
- Number of Contract Sales Reps Down 11.5% in FY2018: JCSOA
April 19, 2019
- GHIT Fund to Leverage Japanese Technology to Benefit Neglected Patients around the World: New CEO
April 18, 2019
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…